Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne

Inclusion Criteria

• •1. Female and male patients, age 15 to 40 years with moderate to severe facial acne vulgaris (IGA score 3-4).
• •2. Patients with skin type I to IV (Fitzpatrick).
• •3. Patients with 20 to 100 inflammatory lesions (papules, pustules, and nodules) on the face excluding lesions on the nose and in the peri-ocular area.
• •4. Patients with up to 200 noninflammatory lesions (open and closed comedones) on the face.
• •5. Patients with no more than 2 nodular lesions on the face.
• •6. Patients who are surgically sterile, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to Day 0. Patients using birth control pills must have used the same product and dose for at least 6 months and must agree to stay with the same product and dose for an additional 6 months.
• •7. Patients must be willing and capable of following study instructions to the extent and degree required by the protocol.
• •8. Patients must sign the approved informed consent form prior to any study procedures.
• •9. Patients must be willing to be photographed. Patients must be willing to sign a photography consent form.